Distinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Daszkiewicz, Lidia ^a,e   Vázquez Mateo, Cristina ^a,f   Rackov, Gorjana ^a   Ballesteros Tato, André ^a,g   Weber, Kathrin ^a   Madrigal Avilés, Adrián ^a   Di Pilato, Mauro ^a   Fotedar, Arun ^b   Fotedar, Rati ^c   Flores, Juana M ^d   Esteban, Mariano ^a   Martínez A, Carlos ^a   Balomenos, Dimitrios ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; GAMMA INTERFERON; OVALBUMIN;

ANIMAL; APOPTOSIS; AUTOIMMUNE DISEASE; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; T LYMPHOCYTE; VACCINIA VIRUS;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; OVALBUMIN; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 84954499422     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07691     Document Type: Article

References (55)

1. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., Elledge, S. J. The p21 Cdkinteracting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993).
2. Brugarolas, J. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557 (1995).
3. Deng, C., Zhang, P.,Harper, J. W., Elledge, S. J., Leder, P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684 (1995).
4. Bygrave, A. E. et al. Spontaneous autoimmunity in 129 and C57BL/6 miceimplications for autoimmunity described in gene-targeted mice. PLoS Biol 2, E243 (2004).
5. Balomenos, D. et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med 6, 171-176 (2000).
6. Salvador, J. M. et al.Mice lacking the p53-effector gene Gadd45a develop a lupuslike syndrome. Immunity 16, 499-508 (2002).
7. Arias, C. F. et al. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol 178, 2296-2306 (2007).
8. Lawson, B. R. et al. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 199, 547-557 (2004).
9. Zhu, B. et al. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J Exp Med 205, 2295-2307 (2008).
10. Chen, H. et al. CD41 T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121, 1549-1560 (2011).
11. Trakala, M. et al. Regulation of macrophage activation and septic shock susceptibility via p21(WAF1/CIP1). Eur J Immunol 39, 810-819 (2009).
12. Scatizzi, J. C. et al. The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages. Eur J Immunol 39, 820-825 (2009).
13. Mavers, M. et al. Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritis. Arthritis Rheum 64, 141-152 (2012).
14. Balomenos, D.,Martinez, A. C. Cell-cycle regulation in immunity, tolerance and autoimmunity. Immunol Today 21, 551-555 (2000).
15. Lloberas, J.&Celada, A. p21(waf1/CIP1), aCDKinhibitor and a negative feedback system that controls macrophage activation. Eur J Immunol 39, 691-694 (2009).
16. Balomenos, D. in Syst. Lupus Erythematosus (Lahita, R. G.) 191-198 (Akademic Press-Elsevier, FL., 2011).
17. Singer, G. G., Carrera, A. C., Marshak-Rothstein, A., Martinez, C., Abbas, A. K. Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model. Curr Opin Immunol 6, 913-920 (1994).
18. Walker, L. S., Abbas, A. K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol 2, 11-19 (2002).
19. Balomenos, D., Rumold, R.&Theofilopoulos, A. N. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101, 364-371 (1998).
20. Peng, S. L., Moslehi, J., Craft, J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 99, 1936-1946 (1997).
21. Kono, D. H., Balomenos, D., Park, M. S., Theofilopoulos, A. N. Development of lupus in BXSB mice is independent of IL-4. J Immunol 164, 38-42 (2000).
22. Kono, D. H. et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-gamma and not Th1/Th2 imbalance. J Immunol 161, 234-240 (1998).
23. Straus, S. E., Sneller, M., Lenardo, M. J., Puck, J. M., Strober, W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 130, 591-601 (1999).
24. Bosque, A. et al. Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. J Leukoc Biol 84, 488-498 (2008).
25. Madkaikar, M., Mhatre, S., Gupta, M., Ghosh, K. Advances in autoimmune lymphoproliferative syndromes. Eur. J. Haematol. 87, 1-9 (2011).
26. Fotedar, R. et al. Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 18, 3652-3658 (1999).
27. McKinstry, K. K., Strutt, T. M., Swain, S. L. The potential of CD4 T-cell memory. Immunology 130, 1-9 (2010).
28. Schoenberger, S. P. CD69 guides CD41 T cells to the seat of memory. Proc Natl Acad Sci USA 109, 8358-8359 (2012).
29. Altman, A., Theofilopoulos, A. N.,Weiner, R., Katz, D. H., Dixon, F. J. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J. Exp. Med. 154, 791-808 (1981).
30. Kyttaris, V. C., Zhang, Z., Kuchroo, V. K., Oukka, M., Tsokos, G. C. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 184, 4605-4609 (2010).
31. Crispin, J. C.&Tsokos, G. C. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol 22, 499-503 (2010).
32. Li, S. et al. The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity 37, 685-696 (2012).
33. Theofilopoulos, A. N., Koundouris, S., Kono, D. H., Lawson, B. R. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 3, 136-141 (2001).
34. Rogers, P. R., Dubey, C., Swain, S. L. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J Immunol 164, 2338-2346 (2000).
35. Katzman, S. D. et al. Duration of antigen receptor signaling determines T-cell tolerance or activation. Proc Natl Acad Sci USA 107, 18085-18090 (2010).
36. Di Pilato, M. et al. New vaccinia virus promoter as a potential candidate for future vaccines. J. Gen. Virol. 94, 2771-6 (2013).
37. Tscharke, D. C. et al. Identification of poxvirus CD81 T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201, 95-104 (2005).
38. Perez, V. L., Lederer, J. A.,Carniel, E., Lichtman,A.&Abbas, A. K. The role of IL12 in helper T-cell differentiation. Res. Immunol. 146, 477-80.
39. Robinson, D. et al. IGIFDoes NotDrive Th1Development but Synergizes with IL-12 for Interferon-c Production and Activates IRAK and NF B. Immunity 7, 571-581 (1997).
40. Sawalha, A. H. et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 9, 368-378 (2008).
41. Chang, C. F. et al. Polar opposites: Erk direction of CD4 T cell subsets. J Immunol 189, 721-731 (2012).
42. Carvalho-Pinto, C. E. et al. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J Immunol 169, 1058-1067 (2002).
43. Crispn, J. C., Tsokos, G. C. Human TCR-alpha beta1CD42CD82T cells can derive from CD81 T cells and display an inflammatory effector phenotype. J. Immunol. 183, 4675-81 (2009).
44. Hedrich, C. M. et al. cAMP-responsive element modulator a (CREMa) transrepresses the transmembrane glycoprotein CD8 and contributes to the generation of CD31CD42CD82 T cells in health and disease. J. Biol. Chem. 288, 31880-7 (2013).
45. Balomenos, D., Rumold, R., Theofilopoulos, A. N. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion. J Immunol 159, 2265-2273 (1997).
46. Fortner, K. A., Budd, R. C. The death receptor Fas (CD95/APO-1) mediates the deletion of T lymphocytes undergoing homeostatic proliferation. J Immunol 175, 4374-4382 (2005).
47. Gupta, V. A., Hermiston, M. L., Cassafer, G., Daikh, D. I., Weiss, A. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J Exp Med 205, 2755-2761 (2008).
48. Selma Dagtas, A., Gilbert, K. M. p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(1) T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology 129, 589-99 (2010).
49. Martin, A. et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7, 591-598 (2005).
50. Barriere, C. et al.Mice thrive without Cdk4 and Cdk2. Mol Oncol 1, 72-83 (2007).
51. Mizui, M. et al. IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8-IL-17-producing T cells. J. Immunol. 193, 2168-77 (2014).
52. Higgs, B. W. et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70, 2029-2036 (2011).
53. Ronnblom, L., Eloranta, M. L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25, 248-253 (2013).
54. Crispin, J. C., Kyttaris, V. C., Juang, Y. T., Tsokos, G. C. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 29, 110-115 (2008).
55. Tang, H., Tan, G., Guo, Q., Pang, R., Zeng, F. Abnormal activation of the Akt-GSK3beta signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus. Cell Cycle 8, 2789-2793 (2009).